Daratumumab is a first-in-class anti-CD38 moantibody approved for relapsed and refractory multiple myeloma [1, 2] and being tested in both smoldering [3] and newly diagnosed myeloma [4]. CD38 is expressed on airway smooth muscle cells, and infusion related reactions (IRRs) were marked by symptoms (cough, wheezing, and rhinorrhea) similar to those of allergic rhinitis. Of all patients treated at 8 and 16 mg/kg in two pivotal trials, the proportion of patients that suffered an IRR was 65% (grade 1-2) and 3% (grade 3-4) in the GEN501 trial [1], and 59% (grade 1-2) and 4% (grade 3-4) in the SIRIUS trial [2]. A pooled analysis of SIRIUS and GEN501 data demonstrated that most IRRs (95.8%) occur during the first infusion, with a decreased incidence of IRRs during second (7%) and subsequent infusions (7%) [5]. There is no relationship between daratumumab serum levels and the development of IRRs [6].
Daratumumab is a first-in-class anti-CD38 moantibody approved for relapsed and refractory multiple myeloma [1, 2] and being tested in both smoldering [3] and newly diagnosed myeloma [4] . CD38 is expressed on airway smooth muscle cells, and infusion related reactions (IRRs) were marked by symptoms (cough, wheezing, and rhinorrhea) similar to those of allergic rhinitis. Of all patients treated at 8 and 16 mg/kg in two pivotal trials, the proportion of patients that suffered an IRR was 65% (grade 1-2) and 3% (grade [3] [4] in the GEN501 trial [1] , and 59% (grade 1-2) and 4% (grade [3] [4] in the SIRIUS trial [2] . A pooled analysis of SIRIUS and GEN501 data demonstrated that most IRRs (95.8%) occur during the first infusion, with a decreased incidence of IRRs during second (7%) and subsequent infusions (7%) [5] . There is no relationship between daratumumab serum levels and the development of IRRs [6] .
The incidence and severity of IRRs has led to the recommended administration rates which result in infusion times for the first, second, and subsequent infusions of 6.5, 4.5, and 3.5 h, respectively [7] . To decrease the IRR rate, one trial tested the addition of 10 mg of montelukast as a premedication prior to the first daratumumab infusion and found the IRR rate was one-third lower in patients who received this leukotriene inhibitor [8] . Beyond slowing the infusion rate, no other clinical trial has successfully reported any intervention to decrease the IRR rate [9] .
Because of the low incidence of infusion reactions after the first infusion, we hypothesized that increasing the infusion rate of the third and subsequent doses of daratumumab would not affect the safety profile. Previously this concept was studied with rituximab in which the second or subsequent infusion was given at a rapid 1 h infusion rate [10] . This led to a rapid rituximab infusion protocol, where patients would be switched if they met certain rapid infusion criteria. With this experience, we developed an accelerated daratumumab infusion protocol with the hypothesis that increasing the infusion rate would not increase the IRR rate beginning with the third dose of daratumumab.
This was a prospective, single-center, and open-label safety study of an accelerated daratumumab infusion in multiple myeloma patients. To be eligible, patients had to have received two or more doses of daratumumab at standard infusion rates; prior IRR's with daratumumab did not exclude patients. The infusion rate was calculated to deliver 20% of the dose over 30 min (200 mL/hr), and then the rate was increased to deliver the remaining 80% over 60 min (450 mL/hr). This resulted in a 90 min estimated infusion time (total volume 550 mL). Per institutional policy, the total volume accounts for manufacturer overfill, and the tubing is primed with drug. Standard vital signs were collected prior to infusion start, every 15 min for 1 h and finally at the end of the infusion. For the first accelerated infusion, patients were observed in the infusion suite for 30 min after infusion completion to assess for a delayed IRR. Existing premedication regimens were not altered for study purposes. Simon's two-stage optimal design was utilized based on the null hypothesis that the IRR-free rate was at most 85% and the alternative hypothesis that it is at least 98%. With a type I error rate of 0.05 and 80% power, the design allowed seven patients to be treated in the first stage, and if no patient experienced ≥grade 3 IRR, an additional 21 patients would be treated. At the end of the study, if none or only one patient out of the total 28 experienced ≥grade 3 IRR, the regimen will be declared safe. IRRs and their respective symptoms were graded as per the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE version 4.03). The protocol was approved by the Ohio State University cancer institutional review board (NCT02944565) and all patients consented prior to treatment.
Patients were enrolled in the beginning of February 2017 and accrual of all 28 patients was completed in June of 2017. Baseline demographics can be found in Table 1 . The median number of prior daratumumab infusions before study enrollment was five. Eight patients received the accelerated rate with their third daratumumab infusion, the earliest allowed per protocol. Eleven patients (39.3 %) had a history of reaction with their first dose with no history of recurrent reaction with their second dose. Premedication regimens with the accelerated dose varied including five patients who did not receive any steroid premedication and three who received reduced doses (less than 12 mg) of dexamethasone when the standard at our institution is 20 mg intravenous. The accelerated infusion was well tolerated among all 28 patients with no grade 3 or above IRRs.
The only treatment emergent toxicity was a single grade 2 hypertension event. This was felt to be related to the volume of fluid being infused over a shorter period of time as the patient had received ten prior doses of daratumumab and had a history of hypertension requiring multiple antihypertensive medications. The accelerated infusion was paused and a diuretic resolved the hypertension. The patient resumed treatment at the previously tolerated rate and subsequently tolerated the accelerated rate. At the 4-week follow up point, all patients remained on the accelerated infusion with no additional toxicities.
The 90-min daratumumab infusion was well-tolerated in multiple myeloma patients receiving their third dose or beyond and saved patients 2 h of infusion time per dose. As depicted in Table 1 , during the protocol accelerated infusion the most common premedication combination was acetaminophen, diphenhydramine, famotidine, and dexamethasone. Since implementing the accelerated infusion as a new standard-of-care at our institution, the premedication strategy involves most standard medications for the first dose (acetaminophen 650 mg oral (po), diphenhydramine 50 mg intravenous (IV) or po, dexamethasone 20 mg IV, montelukast 10 mg po, and famotidine 20 mg IV), pruning the regimen to simply dexamethasone IV and montelukast po with the third dose (first accelerated), then dexamethasone IV only thereafter. Our current practice also avoids testing accelerated daratumumab in any patient whose most recent dose was prepared in the 1000 mL dilution due to moderate or severe IRR. Thus, patients must demonstrate tolerability of a 500 mL daratumumab infusion at the manufacturer recommended rates prior to receiving the accelerated infusion.
Preexisting chronic obstructive pulmonary disease (COPD) constitutes a specific risk factor for bronchospasm. Patients were excluded from daratumumab clinical trials if they had severe asthma or COPD with a forced expiratory volume in 1 s < 60% of predicated. Additional pretreatment with short-and long-acting bronchodilators, or inhaled corticosteroids may further reduce the risk in this group that is at high risk of bronchopulmonary side effects. For our trial, patients with respiratory comorbidities were not excluded from the 90-min infusion.
Because >90% of IRRs occur on the first infusion, the next step could be to test interventions that further decrease the risk of an IRR with the first dose. Anaphylactoid reactions are immediate non IgE-mediated systemic reactions [11] ; for daratumumab, these are thought to be complement activation-dependent resulting from liberation of C3a, C5a, and C5b-9 that leads mast cells and basophils to release symptomatic vasoactive mediators [12] . Thus far antihistamines, corticosteroids, and reduction of the administration rate of pseudoallergenic drugs are the only available interventions, but of drugs that not yet entered the clinic, the 
Delayed dexamethasone use Yes, n (%) 10 (35.7)
APAP acetaminophen, H1A histamine1 antagonist (diphenhydramine or hydroxyzine), H2A histamine2 antagonist (famotidine), LRA leukotriene receptor antagonist (montelukast), DEX dexamethasone complement inhibitor factor H could be considered in this setting [13] . Repeating this trial with the second rather than the third daratumumab infusion is likely to be successful with the majority of the reactions occurring with the first infusion. Strategies such as this to decrease time in the infusion center reduce healthcare resources utilized and increase efficiency in advance of the future use of subcutaneous daratumumab, for which preliminary results have demonstrated decreased IRRs and higher trough levels in patients on chronic therapy [14] . 1 Figure S1a) that exhibit a loss of MLL's H3K4 methyltransferase activity affecting histone modifications and thereby gene transcription [1] . One prominent feature of MLL-rearranged leukemias is the upregulation of the later HOX cluster genes and MEIS1 genes, which expression is crucial in developmental processes like hematopoiesis [1] . In general, the prognosis for these patients is very poor compared to other leukemias [2] . A recent study demonstrated that the canonical nuclear factor-κB (NF-κB) signaling contributes to MLL fusion proteindependent ectopic HOX expression, promotion of proliferation, survival, and differentiation arrest of leukemic cells [3] . Remarkably, some hematological cancers such as multiple myeloma, T-cell leukemia, or Hodgkin ReedSternberg cells show an increased activity of the canonical NF-κB, which might, in some cases, be accompanied by a constitutively active non-canonical NF-κB pathway [4] [5] [6] . Due to the discrete activation of the non-canonical NF-κB pathway by a subset of TNF family receptors, it constitutes an attractive therapeutic target [7] . Therefore, we investigated for the first time the contribution of the non-canonical NF-κB signaling to the survival of MLL-rearranged leukemia cells after chemotherapeutic drug treatment.
To overcome the inherent genetic heterogeneity of MLL patient material, we used primary human CD34+ cord blood cell line transduced with MLL-AF9 fusion cDNA [8] . As reported by Wei et al. [8] , this modified cell line displays a strong similarity to the gene expression profile of cells with MLL-AF9 fusion obtained from patients with AML. To fully assess the non-canonical NF-κB activity in AML with MLL gene rearrangement, we compared transduced cells to closely related, yet non-transduced counterparts, the generally accepted human CD34+ blood stem/progenitor cells [9] . In addition, CD34+ MLL-AF9 cells were compared to another primary human CD34+ cord blood cell line carrying an AML1-ETO rearrangement [10] to evaluate a different type of gene translocation driving AML, but with a better prognosis than MLL-AF9.
Firstly, we analyzed lymphotoxin-β receptor (LTβR) expression, recently reported to be responsible for the aberrant activity of the non-canonical NF-κB in some molecular subtypes of T-cell acute lymphoblastic leukemia [11] , and NF-κB-inducing kinase (NIK) a main regulator of the non-canonical NF-κB pathway. We demonstrated that LTβR indeed exhibits significantly elevated expression only in cells carrying MLL-AF9 rearrangement (Fig. 1a) , but is absent in control CD34+ cells and those with AML1-ETO rearrangement. Induced self-association due to high abundance of LTβR can lead to constitutive NF-κB signaling [11] , therefore we studied further the expression of noncanonical NF-κB components. The analysis revealed that cells with MLL-AF9 rearrangement exhibit a constitutively stabilized NIK possessing the activating phosphorylation (T559). Further, phosphorylated p100 subsequently processed to p52 was observed (Fig. 1a) . Noteworthy in this context, CD34+ MLL-AF9 cells displayed in contrast to the control cells high expression of RelB (Fig. 1a) , which is required for the transcriptionally active non-canonical NF-κB heterodimer (p52/RelB). Consistently, we observed p52 and RelB localization in the nucleus of CD34+ MLL-AF9, but not CD34+ AML ETO cells (Fig. 1b) . Similarly, in primary human CD34+ cord blood cells no nuclear localization of p52 was observed (Supplementary Figure S1b) . Importantly, different AML cell lines with the fusion gene MLL-AF9 (THP-1, NOMO-1, and MOLM13), showed a similar expression and modifications of molecules representative for the non-canonical NF-κB pathway as CD34+ MLL-AF9 cells. In addition, we observed truncated p100 proteins in THP-1 and MOLM13 cells, a feature described in several B-cell leukemia cells (Supplementary Figure S1c) [12] . Overall, our results clearly indicate that AML cells with MLL-AF9 rearrangement display constitutive activation of non-canonical NF-κB facilitated by stabilization and constitutive activation of NIK.
ZFP91, an atypical E3 ubiquitin ligase, is a key regulator of LTβR-dependent non-canonical NF-κB signaling and it mediates K63-linked ubiquitinylation and stabilization of NIK [13, 14] . Consequently, we analyzed the expression of ZFP91 in our primary cell model. Interestingly, ZFP91 exhibited an increased abundance in CD34+ cells with MLL-AF9 fusion, compared to CD34+ control cells and CD34+ cells expressing AML1-ETO oncoprotein (Fig. 1a) . These results are in line with the observation of Unoki et al. [15] , who reported increased ZFP91 expression in more than 90% (27 out of 29) of studied AML cases. Since elevated NIK abundance coincided with the augmented ZFP91 expression in CD34+ MLL-AF9 cells, we next examined whether both proteins interact with each other. A coimmunoprecipitation experiment confirmed interaction between endogenous NIK and ZFP91 in CD34+ cells expressing MLL-AF9 oncoprotein (Fig. 1c) , indicating that ZFP91 indeed regulates stabilization of NIK.
To further elaborate the significance of the stabilization of NIK and its regulator ZFP91 for the survival and maintenance of cells expressing MLL-AF9 oncoprotein, we generated cell lines with a stable knockdown of NIK and ZFP91, respectively, by using short hairpin RNA (shRNA), which were verified by quantitative reverse transcriptase polymerase chain reaction (Supplementary Figure S2a) and by western blot analysis (Supplementary Figure S2b) . Consistent with previous observations by Jin et al. [14] , the ZFP91 depletion caused diminished NIK abundance and phosphorylation (Supplementary Figure S2b) . Importantly, the lack of NIK, but also of ZFP91, caused a significant reduction of p100 processing to p52 ( Supplementary Figure S2b). The phosphorylation of NIK at T559 coincides with its K63-linked ubiquitinylation [14] . Following our observation that NIK phosphorylation decreased significantly upon ZFP91 knockdown, we also evaluated ZFP91-catalyzed K63-linked ubiquitinylation of NIK in CD34+ MLL-AF9 cells after ZFP91 depletion. The analysis revealed that in ZFP91-deficient CD34+ MLL-AF9 cells, NIK showed a strong reduction of K63-linked ubiquitinylation (Supplementary Figure S2c) . Altogether, our result highlights that ZFP91-dependent ubiquitinylation of NIK has an impact on its stabilization and therefore plays a role in the constitutive activation of the non-canonical NF-κB signaling in CD34+ cells expressing MLL-AF9.
To finally decipher the pathophysiological relevance of a stabilized NIK in CD34+ MLL-AF9 cells, we investigated the apoptotic cell death in response to the chemotherapeutic drugs daunorubicin and cytarabine. Although both agents are used in the classical upfront treatment of AML, potential chemoresistance still remains a challenge. At first, we treated the CD34+ MLL-AF9 cells for 48 h with different concentrations of either daunorubicin (10, 25, and 50 nM) or cytarabine (100 and 250 nM) and measured phosphorylation of H2AX at S139 (γH2AX), which indicates induction of DNA damage response (Fig. 2a , Supplementary Figure S3a ). Both treatments caused a dose-dependent increase in γH2AX indicating a rise in DNA damage. Subsequently, we applied daunorubicin or cytarabine on NIK-or ZFP91-deficient CD34+ MLL-AF9 cells and evaluated cleaved caspase 3 as a marker of apoptotic cell death. Remarkably, application of any of these drugs on NIK-or ZFP91-deficient CD34+ MLL-AF9 cells caused a significant increase in cleavage of caspase 3, as compared to control cells (Fig. 2b, Supplementary Figure S3b) , indicating an anti-apoptotic function of NIK and ZFP91 within the non-canonical NF-κB pathway. Of note, the observed decrease in NIK and ZFP91 expression in control cells after treatment could result from a negative feedback loop between NF-κB pathway and caspases [16] . However, the level of cleaved caspase 3 in CD34+ MLL-AF9 cells deficient of NIK and ZFP91 is much higher after treatment as compared to CD34+ control cells. Consistent with the enhanced caspase 3 cleavage, the Annexin V assay revealed that both treatments induced significantly more Annexin Vpositive cells (early apoptotic) when CD34+ MLL-AF9 cells did not express NIK or ZFP91 (Fig. 2c , Supplementary  Figures S3c and d, S4 ). In summary, these results indicate that CD34+ MLL-AF9 cells deficient in either NIK or ZFP91 can be significantly sensitized towards the treatment with chemotherapeutic agents used in clinical settings. Moreover, the constitutive NIK expression observed in MLL-AF9 leukemic cells may in part explain why this type of AML is associated with a poorer prognosis than AML1-ETO-rearrangement leukemia, without constitutive NIK. (N = 9) ). Statistical analysis was performed using Student's unpaired two-sided t-test *P < 0.05, **P < 0.01 Altogether, our data indicate a prominent role of NIK and ZFP91 in the resistance of MLL-AF9 cells to daunorubicin and cytarabine, suggesting that NIK or ZFP91 inhibition should be considered as an additional component in the therapeutic approach to MLL leukemia. 
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Leukemia (2018) [2] . Increasing evidence suggests that aberrations in GATA2 impair its transcription and promoter activation, leading to a loss-of-function, supporting a mechanism of GATA2 haploinsufficiency [3] [4] [5] . Reduced penetrance, the observation that family members carry an identical germline mutation yet display variable clinical manifestations, is common and poses a clinical challenge in the diagnosis and management of familial leukemia's, particularly when identifying "silent" mutation carriers for genetic screening and exclusion as potential stem cell transplant donors [6, 7] . Indeed, we have noted that reduced penetrance is a feature among certain GATA2-mutated MDS/AML families [8] , especially those harboring missense germline mutations such as c.1061C>T (p. Thr354Met) (Table S1 ) although the precise molecular explanation of such occurrence has not been investigated. Analysis of five MDS/AML families harboring p. Thr354Met GATA2 mutations displayed significant intraand interfamilial variations in disease latency, phenotype, and penetrance ( Figure S1 ). These observations suggest that individuals require additional co-operating events for the development of overt malignancy within the context of a shared germline mutation. To investigate this hypothesis further, we examined an extensive five-generation pedigree [9] (Fig. 1a) where two first-degree cousins (IV.1 and IV.6) developed high-risk MDS/AML with monosomy 7, while a third cousin (IV. (Fig. 1b) . This contrasted with the parental generation (III.1, III.5, and III.7) where mutation carriers remain symptom-free with no evidence of hematopoietic abnormality over 60 years of age.
We therefore started with targeted deep sequencing of 33 genes frequently mutated in MDS/AML to define the landscape of secondary genetic mutations across mutation carriers. Notably, while no acquired mutations were detected in asymptomatic family members, all affected cousins analyzed shared an identical somatic ASXL1 mutation (p. Gly646TrpfsTer12) (Fig. 1c) . The variant allele frequency (VAF), however, was lower (12%) in IV.10 and remained stable (range 12-6%) over a 6-year monitoring period. While the co-occurrence of ASXL1 and GATA2 mutations has been proposed as one mechanism for driving the onset and severity of disease symptoms [9] [10] [11] , the low VAF of ASXL1 mutation and stable improvement in hematopoiesis at IV.10 later follow-up suggested that a combination of GATA2-ASXL1 mutation alone is insufficient to promote clonal expansion and leukemic transformation, as this secondary somatic hit may not represent disease progression or identify when treatment is indicated. Intriguingly, apart from the ASXL1 mutation, no other acquired mutations were detected in the 33-myeloid genes assessed in the affected individuals. Moreover, on the basis of our observations and in agreement with previous studies [12, 13] , it seems that monosomy 7 in IV.1 and IV.6 is acquired following acquisition of ASXL1 mutations, hence contributing to the malignancy but not initiating symptoms.
We next considered whether disease symptoms are modulated by endogenous levels of GATA2. Quantitative realtime PCR (qRT-PCR) of bone marrow material demonstrated total GATA2 expression to be significantly lower in the symptomatic (IV.10-yr.1) compared with an asymptomatic carrier (III.7) (Fig. 1d) . Significantly, Sanger sequencing of the cDNA template revealed striking allele-specific expression (ASE), favoring the mutant (T) allele with the absence of the wild-type (WT) (C) allele expression in the symptomatic patient (IV.10), contrasting with biallelic expression in asymptomatic members (III.5 and III.7) (Fig. 1e) . This observation was validated by cDNA cloning of III.7 and IV.10 bone marrow samples and subsequent Sanger sequencing of individual clones ( Figure S2 ). As this suggested that an allelic imbalance in WT:mutant GATA2 expression ratio may account for the variable disease penetrance in this pedigree, we assessed GATA2 expression in IV.10 over a 6-year disease period at four time-points (yr. 1, 3, 4, and 6), demonstrating increased GATA2 expression at later timepoints (yr. 4 and 6) (Fig. 1d) coinciding with reactivation of the WT (C) allele expression (Fig. 1f) and an improvement in hematological parameters, in the absence of any clinical intervention (Fig. 1b) .
To test whether monoallelic GATA2 expression has an impact on the transcriptome driving the onset of disease symptoms, we performed RNA-seq with a view of examining downstream biological features distinctive of GATA2 monoallelic (IV.10-yr.1 and 3) vs. biallelic (IV.10-yr.4 and III.7) groups. Unsupervised analysis revealed a clear separation between GATA2 monoallelic and biallelic samples (Fig. 1g, S3 and Table S2 ). It was noteworthy that certain canonical pathways and gene sets related to tumorigenesis (e.g., DNA replication and cell cycle) were enriched in GATA2 monoallelic vs. biallelic groups ( Figure S4) , potentially reflecting the clinical and phenotypic switch between these two groups. We also noted a significant overexpression of genes with GATA2 cofactor PU.1 motifs in their regulatory regions (p value NES = 2.06) in GATA2 1, 3 , 4, and 6) stained with May-Grünwald Giemsa staining. Magnification: ×20. c Secondary ASXL1 mutations: variant allele frequencies of GATA2 germline mutation and ASXL1 acquired mutation. Samples from three individuals were sequenced: one asymptomatic parent (III.7), one deceased MDS/AML cousin (IV.6), and across three time-points (yr. 1, 4, and 6) from the symptomatic patient (IV.10) reflecting disease evolution. d GATA2 global expression measured by qRT-PCR of bone marrow samples and normalized to healthy bone marrow control: downregulation in IV.10_yr.1 compared with III.7 and downregulation in IV.10_yr.1-3 GATA2 expression compared with IV.10_yr.4-6. The average of five independent experiments is shown. Statistical significance was determined at *p < 0.05, **p < 0.01, and ***p < 0.001 using a t-test with Bonferroni correction. Error bars represent standard error of the mean (SEM). e GATA2 monoallelic expression of the mutant allele in symptomatic (IV.10) vs. asymptomatic carriers (III.5 and III.7), as measured by cDNA sequencing of bone marrow samples. f Correlation of monoallelic GATA2 expression with disease symptoms across the time-points studied in IV.10 with reactivation of the WT allele "C" expression noted 3 years after presentation, concurrent with improvements in hematological parameters. g RNA-seq analysis: principal component analysis (PCA) plot showing a good separation between GATA2 biallelic (green) and monoallelic (blue) groups based on all transcriptomes Fig. 2 Elucidating the molecular mechanisms driving allele-specific changes in GATA2 expression. a(i) A noncoding SNP (rs1806462 [C/ A]) located within the second GATA2 promoter region overlapping a CpG island was detected in the symptomatic (IV.10) but not in asymptomatic members (III.7). a(ii) Given the location of promoter 2 SNP within the 5'UTR, a haplotype between the SNP allele "A" and the germline mutant allele "T" was established, providing a means of distinguishing between mutant and WT alleles in subsequent experiments. a(iii) This promoter SNP [C/A] removes a CpG methylation site in the mutant allele "A" and generates a CpG methylation site in the WT allele "C". b The proportion of methylated CpGs between mutant and WT alleles across the three time-points of IV.10. WT allele is significantly more methylated than the mutant allele in monoallelic samples (yr. 1 and yr. 3), whereas no significant allele-specific differences in methylation were observed in a biallelic-expressing sample (yr. 6). The average of three independent experiments is shown. c Quantification of mutant and WT allele ChIP sequence peak heights across the time-points of IV.10 based on Sanger sequencing. H3K4me3 activation mark favoring the mutant allele was enriched in monoallelic samples (yr. 1 and yr. 3) compared with the biallelic sample (yr. 4). The average of three independent experiments is shown. Statistical significance was determined at *p < 0.05, **p < 0.01, and ***p < 0.001 using a t-test with Bonferroni correction. NS corresponds to nonsignificant comparisons. Error bars represent SEM biallelic vs. monoallelic samples, in support of a recent finding [14] that p.Thr354Met mutants bind and interact with PU.1 more tightly than WT, thus leading to sequestration of PU.1 from its normal cellular functions. Consequently, the transcriptional activation triggered by PU.1 will be diminished in our GATA2 monoallelic samples.
The differences observed in these gene-expression profiles prompted us to explore the molecular mechanisms underlying monoallelic GATA2 expression. We hypothesized that these allele-specific changes in GATA2 expression are driven by transient epigenetic mechanisms that include changes in DNA methylation and chromatin mark deposition. A CpG singlenucleotide polymorphism (CpG-SNP) (rs1806462) [C/A] located within the promoter and 5′UTR of GATA2 overlapping a CpG island offered a marker to distinguish between mutant and WT alleles where this SNP creates/abolishes a CpG dinucleotide within the GATA2 promoter region (Fig. 2a) . More specifically, cDNA sequencing of 5′UTR allowed us to define haplotypes, where the promoter SNP allele (A) resides on the germline mutant GATA2 allele (T) (Fig. 2a(ii) ). Apart from IV.10, no other family members and only 2/12 individuals from pedigrees presented in Figure S1 were heterozygous for this SNP (one of whom is an asymptomatic carrier). Therefore, we do not infer that this haplotype would contribute to the progression of symptoms. Instead, we used this SNP to determine whether allele-specific differences in DNA methylation could explain the silencing of WT GATA2 allele expression observed in earlier time-points of IV.10. As illustrated in Fig. 2b and S5, bisulfite sequencing of a 200-bp region encompassing rs1806462 demonstrated a significant increase in promoter methylation in the WT allele of IV.10 in yr. 1 and yr. 3 following diagnosis, in contrast with the absence of allele-specific differences in methylation at a later time-point.
We next sought to establish whether these allele-specific changes in GATA2 methylation and expression are accompanied by changes in chromatin structure at the promoter. H3K4me3 and H3K27me3 define poised or closed chromatin, respectively, rendering them more or less accessible for transcription factors, thereby regulating gene expression [15] . The deposition of these bivalent marks was assessed in IV.10 by allele-specific chromatin immunoprecipitation (ChIP) followed by Sanger sequencing within GATA2 promoter region encompassing the SNP rs1806462 [C/A]. While there were no apparent allele-specific differences in H3K27me3 deposition across the different time-points of IV.10, an enrichment in the deposition of H3K4me3 on the promoter of the mutant allele (A) relative to the WT allele (C) was noted in IV.10 monoallelic samples (yr. 1 and 3) (Fig. 2c, S6 and S7 ). In contrast, and consistent with the pattern observed with DNA methylation, there was no demonstrable difference in H3K4me3 deposition in the IV.10 biallelic sample (yr. 4), coinciding with reactivation of the WT allele expression and an overall improvement in clinical parameters. We believe that these observations are in keeping with the notion that H3K4me3 occupancy inhibits de novo DNA methylation [16] which was borne out by subsequent bisulfite sequencing of H3K4me3-enriched DNA from our ChIP experiments, demonstrating that DNA methylation and H3K4me3 deposition are mutually exclusive in our IV.10 samples ( Figure S8) .
Collectively, our findings provide a step forward in understanding the molecular mechanisms underlying reduced penetrance in GATA2-mutated MDS/AML pedigrees, which may be governed by the acquisition of additional co-operating mutations (e.g., ASXL1) combined with dynamic epigenetic reprogramming and subsequent allele-specific expression of GATA2 mutant allele, adding another level of complexity to the (epi)genetic basis of familial MDS/AML.
Acknowledgements We are indebted to the family investigated in this study whose members have kindly donated samples for research. We also thank all the clinicians who have looked after this family over the years. to offer a growth and/or survival advantage over other unaffected HSCs [3, 4] in the context of immune-mediated bone marrow failure [5] explaining the unique association of PNH with aplastic anemia (AA). Recently, additional mutations in genes other than PIGA were identified in PNH clones, offering an explanation for intrinsic expansion drive of PNH clones irrespective of or after the initial immune escape occurred [6] . Multiple PIGA mutations have been discovered at very low frequencies in healthy individuals [7] , as well as in isolated reports of occasional PNH patients [8, 9] and thus observation did not lead to the appreciation that the phenomenon of an oligoclonal disease origin may be ubiquitous and potentially essential for the pathogenesis of PNH. PIGA mutant cells fail to expand in engineered animal models [10] , suggesting that additional permissive conditions and factors are required for PNH clone evolution. Using next generation sequencing (NGS) of the PIGA gene and cell sorting by flow cytometry, our goal was to determine if we could improve PIGA mutant clone detection and gain insight into PNH clonal dynamics through longitudinal monitoring. According to theoretical stipulations~20% patients may harbor >1 PIGA mutant hematopoietic stem cell (HSC) [11] . The recently described acquisition of multiple lesions at HLA loci in AA represents an analogous scenario of immune evasion and somatic adaptability of HSCs [12, 13] .
We set out to experimentally challenge this hypothesis, and determine if, in addition to the classic two-hit scenario characterized by a founder PIGA mutation followed by a subclonal driver hit, there are more complex, potentially mosaic, clonal dynamics; whereby multiple PIGA clones compete for dominance. We also asked whether stratifying AA/PNH and classic PNH patients would provide additional insight as to the process of clonal selection.
Patients with PNH and AA were diagnosed according to current clinical guidelines and following informed consent enrolled into this study, as detailed in supplemental data. Using flow cytometry to identify PNH clones, 133 patients with PNH (N = 33), AA with small PNH clones >0.5% of WBCs (N = 33), and AA/PNH (N = 67) were studied (Table S1 ). Mean WBC PNH clone sizes were 77%, 0.22%, and 27%, respectively. DNA was extracted and subjected to multi-amplicon deep sequencing of PIGA using primers covering all exons of the PIGA gene (Table S2) . Using deep NGS analysis, 223 mutations in the PIGA gene were detected (Fig. 1a) . Frameshift (35%, N = 78) and missense mutations (34%, N = 77) were most common, followed by splice site (14%, N = 31), nonsense (13%, N = 30), and nonframeshift insertion/deletion (3%, N = 7) mutations.
As detection rates correlate with PNH clone size in WBCs (P < 0.0001, chi-square, Figure S1 ), sorting PNH positive and negative cells by flow cytometry (Figure S2 ; PNH N = 12, AA/PNH N = 17; mean purity 97.3%, SD 4.2%, Table S3 ) significantly increased the number of mutations detected by NGS (Fig. 1b, top left) . The number of mutations detected per patient in the flow sorted population ranged between 0 and 12 with a mean double that of whole blood (2.8 vs. 1.4, P = 0.003, t-test). This effect was statistically significant in males (Fig. 1b , bottom left, P < 0.001), as PIGA is located on chromosome X, and while a similar increase in mutation detection was observed in females, the difference was not statistically significant. Of the sorted subcohort, we detected PIGA mutations in 25 out of 29 patients (86%), with the undetected balance likely being PIGA deletions larger than 250 bp that are not detectable by NGS [14] . Thus, previous approaches to PNH may have underestimated the prevalence of multiple PIGA mutations, which we define as PIGA clonal mosaicism.
The presence of multiple mutant PNH clones in a single patient has been reported in the literature [8, 9] , and has been inferred from the presence of both Type II and III GPIdeficient clones. In a representative patient from our cohort (Fig. 1b, center and right) , Type II and III PNH cells are clearly derived from 2 codominant yet distinct clones; one characterized by a missense mutation (c.T512G, the Type II PNH clone), and a second with a frameshift deletion (c.438delG, the Type III PNH clone), and a 3rd splice site mutation in a minor clone within the Type III fraction. These results reinforce the notion that PNH is not a monoclonal disease, using current methods that allow for an ex vivo "snapshot" of a patient at a precise moment in time, thus supporting previous research using older techniques dependent on extensive in vitro T cell cultures [8, 9] .
Although there are many hypotheses as to the pathogenesis of PNH, the association of PNH with AA strongly suggests that PNH emerges within immune-mediated bone marrow failure [5, 15] . Multiple PIGA mutations suggests that in AA/PNH, where immune selection pressure is putatively most pronounced, a higher number of PIGA mutant clones should be detectable. Cross sectional analysis at the initial sampling of the entire cohort demonstrates that there is an association by linear regression between WBC clone size by flow cytometry and the number of mutations detected by PIGA NGS in unsorted whole blood (Fig. 2a , left, linear regression R 2 = 0.36, P < 0.0001). Regression analysis incorporating longitudinal sequencing results (AA/ PNH, N = 29, observance range 3-127 months, median 41 months; PNH, N = 18, range 2-131 months, median 62 months, Table S1) suggests that, as time progresses, the number of mutations detected in AA/PNH increases or plateaus (Fig. 2a , right top, P = 0.012), although correlation is not strong (R 2 = 0.03). In contrast, the trend is reversed in classic PNH, with the number of mutations detected decreasing over time (Fig. 2a, bottom , P < 0.0001), and a stronger inverse correlation between the time since diagnosis and the number of mutations (R 2 = 0.21). Although this analysis warrants validation in a larger prospective study often precluded due to the rarity of PNH, our data suggest a general trend toward the eventual dominance of a single PIGA mutant clone in classic PNH. It is possible that such a mechanism also operates for AA with multiple HLA class-I mutant clones [12, 13] .
Analysis of representative examples with long-term longitudinal monitoring illustrates a contrast between AA/ PNH (Fig. 2b, left) and classic PNH (Fig. 2b, top right) (additional patients depicted in Figure S3 ). Mutations can fluctuate in the contribution to the overall PNH clone size over time with some mutations increasing while others Fig. 2 Longitudinal analysis and clonal dynamics of PIGA mutations. Cross sectional analysis at the earliest available sample by linear regression demonstrates an association between the number of PIGA mutations detected in whole blood and the WBC clone size by flow cytometry (a, left). Despite this association, linear regression of the number of mutations against the time from diagnosis differs in AA/ PNH patients (a, top right) when compared to patients with a classic PNH diagnosis (a, bottom right). Representative AA/PNH patient followed longitudinally with complex clonal dynamics more common in AA/PNH (b, left) in contrast to the emergence of a dominant clone in classic PNH (b, right top), a trend more prevalent in PNH than AA/ PNH (b, bottom right, 55% (10/18) vs. 38% (10/28), respectively, P=0.06). Schematic fish plot derived from data illustrating the emergence of a dominant clone from six distinct PIGA mutations in classic PNH (c) decrease in AA/PNH (Fig. 2b, left) . When we examined the entire longitudinal cohort, in PNH patients a dominant clone (defined as >2×the remaining VAF) was present at the baseline measurement or emerged over time (10 out of 18, 55%), while in AA/PNH only 10 out of 28 (36%) exhibited this trend (Fig. 2b , bottom right, P = 0.06, t-test), suggesting that AA/PNH patients tend to display more complex clonal dynamics whereby multiple clones contract or expand. While there are generally exceptions to a rule, it may be that active immune pressure in AA/PNH may allow for observation of complex clonal dynamics that are not present in classic PNH, and it remains to be understood if cases of AA/PNH and classic PNH exist in a continuum.
Overall, our data suggest that PNH begins in an oligoclonal state in which multiple PIGA mutant clones compete to emerge. Thus PIGA mutation and the resultant GPIdeficiency exemplifies another way of immune escape in AA similar to that proposed for somatic HLA mutations or LOH (Fig. 1c) , while in classic PNH the evolution may follow a different path. Surviving PIGA mutant clones may gain intrinsic additional growth advantages due to secondary mutations in other genes [6] , knowledge of which may determine the best treatment modality. In other cases, ongoing immune attack may be the dominant pathology requiring treatment. Whether HLA mutant clones also experience intrinsic amplification by additional somatic events remains unknown. It would be interesting to investigate whether similar immune selection pressure is exerted during immune checkpoint inhibitor therapy.
PIGA mutation detection by NGS is more sensitive if sequencing analysis of PIGA mutant clones is performed on sorted rather than unsorted cell populations. This approach was used here to detect multiple mutations with the same phenotype, as well as those with coexistent Type II and Type III phenotypes, a result consistent with studies in healthy individuals and PNH patients demonstrating the pre-existence of multiple PIGA mutations [7] [8] [9] . In contrast to otherwise reasonable speculation whereby new clones evolve to replace exhausted, older hematopoietic clones, we illustrate that it is more likely that there is a preexisting PIGA mutated pool initially, and that over time, a single dominant clone emerges in classic PNH. 
Tumor suppressor genes 
CMML-BP treatment strategies and responses
Treatment details were available in 157 (92%) patients and included best supportive care 39 (BSC, 25%), HMA therapy 16 (10%), AML-like induction chemotherapy 59 (38%), AML-like induction chemotherapy followed by allogeneic HCT 23 (15%), upfront allogeneic HCT 2 (2%), and clinical trials in 18 (11%) (Supplementary  table 4) . Twenty-nine (38%) patients had prior 5-azacitidine exposure for a median of 6 cycles (range, 2-24), while 50 (65%) patients had prior decitabine exposure for a median of 12 cycles (range, 1-50), with 2 patients having received both agents sequentially. In the azacitidine-treated patients, 33% achieved a CR, 11% a partial response (PR), 48% had stable disease, while 8% had disease progression on therapy. In the decitabinetreated patients, 60% had a CR, 12% PR, 21% stable disease, while 7% had disease progression on therapy. Among the 8 patients that went on to get post CMML-BP HMA therapy, 4 (50%) had received prior azacitidine with all 4 having stable disease, while 4 (50%) had received decitabine with 50% CR, 25% PR and 25% with stable disease. Twenty-five (16%) patients went on to receive HCT, with 40% being in a CR and 12% having CRi at the time of HCT (supplementary table 5 ). At last follow-up, 19 (76%) deaths were reported, with a median relapse-free survival (RFS) of 7 months and a median OS of 10 months; with no difference in RFS (p = 0.8) or OS (p = 0.7) between patients that received a MA versus RIC. CMML-BP treatment response was assessable in 113 
CMML-BP survival outcomes
After a median follow-up of 4.4 months (range 0-122), 141 (82%) deaths were recorded. Median OS was 6 months with 1-, 3-, and 5-year survival rates of 25%, 9%, and 6%, respectively. Survival trends were similar (p = 0.4) for patients diagnosed prior to and after the year 2006 (Fig. 1a) .
In patients that received AML-like induction chemotherapy (n = 55), survival outcomes were dismal regardless of response (Fig. 1b) . Similarly, with the exception for a modest survival benefit for patients undergoing allogeneic HCT (5-year survival rate 21%), survival with BSC, AMLlike induction chemotherapy alone, HMA and clinical trials was dismal (Fig. 1c) . In the allogeneic HCT group, patients that had ELN adverse risk cytogenetics at CMML-BP had an even shorter survival in comparison to those with ELN intermediate risk cytogenetics (Fig. 1d) . Ninety-two percent of post HCT deaths were due to disease relapse. In univariate analysis of variables recorded at time of CMML-BP, risk factors adversely impacting survival included older age (p = 0.04), lower hemoglobin (p = 0.02), PB blast % (<0.0001), ELN high-risk cytogenetics (p = 0.007), prior exposure to HMA (p = 0.006), failure to achieve CR/CRi (p = 0.0006), and not undergoing HCT (p = 0.0011). Gene mutations, including FLT3-ITD (p = 0.4), cytogenetic clonal evolution (p = 0.3), and molecular clonal evolution (p = 0.4), did not impact survival. In multivariable analysis, only PB blast % (PB blasts ≥ 20%, p = 0.0005, HR 2.2, 95% CI 1.4-3.4), prior exposure to HMA therapy (p = 0.002, HR 1.9, 95% CI 1.2-2.1), ELN high-risk cytogenetics (p = 0.03, HR 1.5 (95% CI 1.1-2.3), and failure to achieve CR/CRi CMML-BP is associated with high morbidity and poor outcomes [2, 6, 12] . In this study of 171 CMML-BP patients, the median OS was 6 months with a 5-year survival rate of 6%. Although with time, advances have occurred in clinical therapeutics; in our study survival in CMML-BP was not significantly different based on the calendar year of diagnosis. CMML-BP patients were treated with a variety of modalities and with the exception for a modest survival benefit with allogeneic HCT (5-year survival rate 21%), survival outcomes with all other modalities remained dismal (5-year survival rates <10%). Eighty-one (47%) patients had prior exposure to HMA with 33% having achieved CR prior to CMML-BP; indicating the ineffectiveness of these agents in altering the natural course of this disease. In a recent study, serial sequencing demonstrated that responses to HMA in CMML were associated with changes in DNA methylation and gene expression, without any changes in the mutational allele burdens [13] .
In the current study, we demonstrate that prior exposure to HMA was an independent factor adversely impacting post CMML-BP survival; although one may argue that these patients already had aggressive disease biology, necessitating the earlier use of HMA. Additional negative prognosticators included ELN high risk cytogenetics, PB blast % ≥20 and failure to achieve CR/CRi with induction chemotherapy. Neither did cytogenetic clonal evolution, nor molecular clonal evolution, impact survival. Although, the achievement of CR/CRi after induction chemotherapy was found to have a favorable impact, the overall durability of response was limited (median OS 9.8 months). Allogeneic HCT was successfully carried out in a small fraction of CMML-BP patients (15%); with patients that had adverse cytogenetic findings at CMML-BP demonstrating a trend toward inferior survival. These data support the earlier use of allogeneic HCT in eligible patients, preferably before blast phase disease. The response rates to HMA use after CMML-BP were strikingly dismal with 0% CR and 17% CRi; suggesting that these patients should not be reexposed to these agents.
In summary, ours is the largest-to-date study, describing the clinical and molecular correlates and dismal outcomes of patients with CMML-BP disease. These results serve as a critical benchmark for future clinical trial design and conduct.
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